|
Lawrence Schachner; Alyssa Feiner; Sam Camisulli
The "Clinical
Snapshot" series provides a concise examination of a clinical
presentation including history, treatment, patient education, and
nursing measures. Using the format here, you are invited to submit your
"Clinical Snapshot" to Dermatology Nursing.
Epidermolysis bullosa (EB) is the term given to a group of
inherited mechanobullous disorders involving blistering of the skin and
sometimes mucous membranes in response to minor frictional trauma.
There are three types of EB: simplex, junctional, and dystrophic. Each
form has a specific cleavage plane within the epidermal-dermal basement
membrane zone, as well as specific clinical manifestations. Each form
of EB has distinguishing pathophysiology, mode of inheritance, and
prognosis (Tidman & Garzon, 2003).
In all forms of EB simplex (EBS), blisters form by
cytolysis of the infranuclear portion of the basal keratinocytes.
Currently there are approximately seven variants of EBS, each with
specific clinical manifestations. EBS Weber-Cockayne is a variant with
blistering confined primarily to the palms and soles. EBS Koebner is a
different variant with widespread blistering at sites of friction. EBS
Dowling-Meara is a form of the disease with neonatal widespread
blistering progressing to blistering in characteristic clusters. EBS is
inherited in an autosomal dominant manner with a few exceptions. The
prevalence of EBS in 2001 based on a Scotland study was determined as
33.2 cases per million of the population, and the incidence between
1960 and 1999 was 34.4 per million live births. The figures from the
National EB Registry are 4.6 cases per million of the population and
10.75 per million live births. The Weber-Cockayne and Koebner variants
account for the majority of EBS cases. These variants as well as
Dowling-Meara (the most severe type of EBS) and mottled pigmentation
variants are caused by mutations in the genes encoding keratins 5 or
14. These are the genes that constitute and are expressed by the
cytoskeleton of basal keratinocytes (Tidman & Garzon, 2003).
Junctional epidermolysis bullosa ( JEB) is a variant of EB
where the cleavage plane is in the lamina lucida of the epidermal
basement membrane. The usually lethal form of JEB is called
JEB-Herlitz. All types of JEB are inherited in an autosomal recessive
manner. JEB is the rarest form of EB with a prevalence of 0.3 cases per
million of the population and an incidence of 3.2 new cases per million
live births. The U.S. equivalent figures are 0.44 and 2.04. The type,
location, and severity of blistering varies based on the type of JEB.
JEB is usually due to mutations in genes encoding laminin 5, which
morphologically are the anchoring filaments that cross the lamina
lucida (Tidman & Garzon, 2003).
Dystrophic EB (DEB) is a result of a mutation in the gene that
encodes type VII collagen, the anchoring fibrils that unite the lamina
densa with the underlying elements of the papillary dermis. The
clinical severity of DEB as well as in all the other major variants of
EB is based on the type of mutation, where the mutation is within the
protein molecule, as well as other mutations that may be clinically
silent. The bullae in DEB usually heal with scarring and transient
milia, and are usually associated with some degree of nail dystrophy.
DEB may be inherited as autosomal dominant or autosomal recessive
conditions. The prevalence based on the Scottish study is 24.6 cases
per million of the population (2.4 cases per million in the United
States) and the inci-dence is 26.4 new cases per million live births.
Most of the cases are the dominant form of DEB. The clinical picture in
each type varies. In dominant DEB, usually bullae manifest over acral
bony prominences. During healing, milia develop with subsequent
atrophic scarring. Thickened nail plates with scarring and eventual
loss of the nail is seen. There may be oral bullae and involvement of
the gastrointestinal tract as well (Tidman & Garzon, 2003).
There is no specific treatment for any of the variants of EB.
Care for patients with EB is fundamentally preventative and symptomatic
(see Table 1 ). The current treatment strategies focus on preventing
the formation of new blisters, preventing and treating infections,
facilitating wound healing, providing nutritional support, managing
extracutaneous complications, and maintaining and providing a strong
psychological support system to patients and family members (Tidman
& Garzon, 2003).
References
Tidman, M., & Garzon, M. (2003).
Vesiculobullous disease. In L.A. Schachner & R.C. Hansen (Eds.),
Pediatric dermatology (3rd ed.) (pp. 683-692). St. Louis, MO: Mosby.
Lawrence
Schachner , MD , is a Professor of Dermatology and Pediatrics, and
Director, Division of Pediatric Dermatology, University of Miami School
of Medicine, Miami, FL.
Alyssa Feiner , MD , is a Medical Student, University of Miami School of Medicine, Miami, FL.
Sam Camisulli , MD , is a Dermatology Resident, University of Toronto, Toronto, Ontario, Canada
|